April 15th 2024
Damien Bailly, president of established markets at Astellas, discusses why partnerships and collaborations are a critical organizational—and wider ecosystem—imperative in ensuring that patients have access to the medicines they need.
Lundbeck's Taj Bhardwaj: Market Access and Mental Health
December 17th 2019Lundbeck executive Taj Bhardwaj talks about the differing mindsets necessary to lead local and global-level market access strategy in pharma-and how his current company is committed to stay in the fight to advance new treatments and break down stigmas in mental health.
Unprecedented Times for Market Access: Amy Mahery
December 16th 2019Amy Mahery, last month appointed Global Head of Market Access and Pricing of the healthcare business of Merck KGaA, Darmstadt, Germany, discusses her key priorities and how she will draw on her multi-faceted industry experience to approach the challenges ahead.
Shifting Approaches from Traditional R&D to Platform
October 1st 2019Bernhardt Zeiher, Chief Medical Officer of Astellas discusses how the company transitioned from a traditional R&D approach to a platform approach, the need for innovation models to change in pharma, and the impact academia has on drug development.
Better Diagnostics and Treatments for Dementia: Rachel Dolhun, The Michael J. Fox Foundation
September 19th 2019Rachel Dolhun of The Michael J. Fox Foundation for Parkinson’s Research tells Pharm Exec about how she helps the Foundation to mobilize greater research engagement on both individual and community levels.
The Call to Cure: Geoff MacKay, AVROBIO
August 12th 2019Pharm Exec speaks with Geoff MacKay, co-founder and CEO of AVROBIO, about the company’s mission to advance potentially curative lentiviral-based gene therapies, his career building businesses and innovation in regenerative medicine, and his most important quest to date-moving gene therapy into the mainstream.